Multidrug Resistant Bacteria in the Community: An Update

David van Duin[1,*], **David L. Paterson**[2]

[1.]Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, United States of America

[2.]University of Queensland Centre for Clinical Research, Brisbane, QLD, Australia

Abstract

Multidrug resistant (MDR) bacteria are one of the most important current threats to public health. Typically, MDR bacteria are associated with nosocomial infections. However, some MDR bacteria have become quite prevalent causes of community-acquired infections. These may be pathogens which are classically community acquired such as *Neisseria gonorrhoeae*, *Shigella*, *Salmonella* and *Streptococcus pneumoniae*. Indeed, MDR *N. gonorrhoeae* is now regarded by the CDC as an urgent threat. The community spread of MDR bacteria, more typically associated with healthcare environments, is also a crucial development. Methicillin-resistant *S. aureus* (MRSA) and extended-spectrum beta-lactamase (ESBL) producing *E. coli* are the most prevalent of such bacteria. The prevalence of these is driven by person to person transmission in the community and, in the case of ESBL producing *E. coli* by the use of antibiotics in agriculture. An important global threat on the horizon is represented by production of carbapenemases by community-acquired hypervirulent *Klebsiella pneumoniae*. Such strains have already been found in Asia, Europe and North America. Prevention of further community spread of MDR bacteria is of the utmost importance, and will require a multi-disciplinary approach involving all stakeholders.

Keywords

Introduction

Multidrug resistant (MDR) bacteria are well-recognized to be one of the most important current public health problems. More than 2.8 million antibiotic resistant infections occur in the United States each year, accounting for 35,000 deaths[1]. Rising rates of antibacterial resistance have an impact on all aspects of modern medicine, and compromise the results of cancer care, transplantation and surgical procedures[2]. Although difficult to accurately calculate, there are also substantial economic costs to antibiotic resistance. This may result from extended duration of hospital stay, the need for greater outpatient follow-up and the higher costs of new drugs needed to treat MDR bacteria[1]. Unfortunately the occurrence of

[*]**Corresponding author:** David van Duin, MD, PhD, Division of Infectious Diseases, CB 7030, University of North Carolina, 130 Mason Farm Road, Chapel Hill, North Carolina 27599, United States of America, Telephone: 919-843-2200, Fax: 919-966-6714, david_vanduin@med.unc.edu.

specific MDR bacteria is closely linked to the use of broad spectrum antibiotics, both for empiric as well as for definitive therapy[3]. This increased use in turn leads to even higher rates of MDR bacteria, thus creating a vicious cycle.

Typically, MDR bacteria were associated with nosocomial infections. However, some MDR bacteria have become quite prevalent causes of community-acquired infections. This is an important development as community spread of MDR bacteria leads to a large increase of the population-at-risk, and subsequently an increase in the number of infections caused by MDR bacteria. In addition, when the incidence of a certain resistance pattern in bacteria causing community-acquired infections exceeds a specific threshold, broader spectrum antibacterials and/or combination antibacterial therapy are indicated for the empiric treatment of community-acquired infections. In this review, we will outline the trends in and epidemiology of community prevalence of various MDR bacteria.

Community-associated, health-care associated and nosocomial infections

Infections can be divided into community onset and nosocomial acquisition. The widely used cut-off to distinguish between these two categories is whether the onset of infection was within the first 48 hours of hospitalization (community-onset) or later (nosocomial). Limitations of this division include the arbitrary nature of the 48 hour time point, as well as the dependence on the timing of diagnosis. If cultures are performed earlier during hospitalization, more infections are likely to be labeled as community-onset.

The category of community-onset can then be further subdivided into community-acquired and healthcare-associated, based on work pioneered by Morin et al. and Friedman et al [4, 5]. Generally, an infection is deemed to be healthcare-associated if a patient was hospitalized in an acute care hospital for two or more days within 90 days of the infection; resided in a nursing home or long-term care facility; received recent intravenous antibiotic therapy, chemotherapy, or wound care within the past 30 days of the current infection; or attended a hospital or hemodialysis clinic [6].

The remaining category includes those patients who have a community-onset infection, and who do not meet any of the above criteria for health-care associated infection. These infections are considered to be community-acquired. However, for the purposes of evaluating MDR bacteria in the community, these definitions may not tell the whole story. Patients tend to get infected with organisms with which they were previously colonized. Therefore, it is the timing of colonization, rather than the timing of diagnosis of infection that is crucially important to determine the origin of the MDR bacteria. Studies that have employed screening of non-infected individuals have addressed these questions for some MDR bacteria in certain populations.

Antibiotic resistance in bacteria typically regarded as community-acquired

Antibiotic resistant sexually transmitted infections

Multidrug resistant bacteria that cause sexually transmitted infections (STIs) have become increasingly prominent in recent years. Drug resistant *Neisseria gonorrhoeae* is now

regarded by the CDC as an urgent threat (Table 1) and is estimated to infect 550,000 Americans annually [1]. While antibiotic resistance in *Chlamydia trachomatis* and *Treponema pallidum* does occasionally occur, these organisms are not renowned as being MDR. In contrast, an emerging pathogen, drug resistant *Mycoplasma genitalium*, is on the CDC's "watch list" due to its propensity for multidrug resistance. It should also be noted that bacteria that cause gastrointestinal illness may be sexually transmitted – MDR shigellosis is increasingly recognized as an issue for men who have sex with men [7].

There are a number of reasons why MDR in bacteria that cause STIs has become so prominent. This includes availability of antibiotics without a prescription in many parts of the world and reliance of treatment that is typically empiric, either based on symptoms or culture independent methods for laboratory diagnosis. In recent years, molecular methods for rapid diagnosis of antibiotic resistance genes in *N. gonorrhoeae* and *M. genitalium* have been developed [8, 9]. This could improve surveillance and may allow more targeted treatment choices.

Antibiotic resistant gastrointestinal infections

Clostridioides difficile is regarded by the CRC as an urgent AMR threat. Further discussion on this pathogen is beyond the scope of this article. Drug resistant *Campylobacter*, nontyphoidal *Salmonella* and *Shigella* are all serious AMR threats. They infect more than 700,000 people in the United States annually. The use of antibiotics in agriculture with subsequent entry of AMR pathogens (or genes) into human food is the usual means by which these MDR pathogens infect humans. In contrast, in the United States and Western Europe, patients with drug-resistant *Salmonella* serotype Typhi have typically traveled internationally.

One of the key challenges associated with treatment of antibiotic resistant gastrointestinal infections and STIs is provision of alternatives to orally administered fluoroquinolones and macrolides when resistance is present. Some new antibiotic options are now under development which are hoped to address this need.

Antibiotic resistant respiratory infections

Streptococcus pneumoniae is the most common cause of community-acquired pneumonia and drug-resistant *S. pneumoniae* infects more than 900,000 Americans annually. In response to this threat, new antibiotics, including delafloxacin, omadacycline, lefamulin, solithromycin, nemonoxacin, and ceftaroline, have recently been approved or are in clinical development[10]. Drug-resistant tuberculosis, an enormous global health problem, is beyond the scope of this article.

Antibiotic resistant organisms classically described in hospitals but now found in the community

MRSA

Methicillin-resistant *S. aureus* (MRSA) is probably the best example of a prevalent and important MDR bacterium that has successfully transitioned from an almost exclusively

nosocomial setting to being widespread in the community. The epidemiology of community-associated MRSA (CA-MRSA) has been extensively reviewed elsewhere[11, 12]. Here, we will give a brief overview of MRSA in the community as it may be predictive of the behavior of other MDR bacteria.

As early as 1982 an outbreak of CA-MRSA was reported in Detroit[13]. In this outbreak, more than half of patients were intravenous drug users, and the remaining patients had several comorbidities that put them at risk. Importantly, various different strains were found in this outbreak[13]. It was not until the early 1990's that more genuine CA-MRSA outbreaks began to be reported. These outbreaks occurred in populations without specific risk factors. The MRSA strains involved were generally monoclonal or oligoclonal and rather than being extensively multidrug resistant such as nosocomial MRSA strains at that time, these CA-MRSA strains were susceptible to many non-β-lactam antibiotics. In the early 2000's, a new strain of CA-MRSA – USA300 – became the predominant CA-MRSA in the United States, effectively replacing the previous USA400 CA-MRSA strain[11]. This USA300 strain is characterized by the presence of the staphylococcal cassette chromosome mec (SCCmec) type IV as well as of genes encoding for Panton-Valentine leucocidin (PVL) toxins[14]. Households are an important reservoir for the USA300 strain. In a recent study that utilized whole genome sequencing data, USA300 MRSA was shown to persist in households between 2 and 8 years prior to admission of a symptomatic patient from that household, and to continue to persist for at least another year after that[15]. This and other evidence shows conclusively that this specific strain of MRSA has been able to become entrenched in a community setting in the absence of ongoing antibiotic pressure. In addition, specific strains of CA-MRSA have been shown to be associated with exposure to lifestock; so-called lifestock-associated (LA) MRSA. The ST398 LA-MRSA is predominantly found in Europe and America, whereas ST9 LA-MRSA is encountered in Asia[16].

Vancomycin-resistant Enterococci (VRE)

Vancomycin-resistant enterococci (VRE) emerged in the late 1980's, and became a common cause of nosocomial infections in the 1990's[17]. Studies in the 1990's did not detect the presence of vancomycin resistance in enterococci isolated from subjects without healthcare exposure in the United States[18, 19]. In contrast, in European studies from the same time period, VRE was detected in the stool of healthy volunteers[20]. In addition, VRE was commonly found in European food animals[21, 22]. The underlying reason for this difference between Europe and the United States is the use of avoparcin – a glycopeptide antibiotic – for the purpose of promoting growth in food animals. Avoparcin was never approved for use in the United States or Canada, but its use was widespread in Europe up to 1997[22]. After a ban on avoparcin in animal husbandry, rates of VRE in both animal samples, as well as in samples from human volunteers started to decrease[20, 22]. These important data illustrate the critical link between antibiotic use in the food industry and antimicrobial resistance rates in humans. It also indicates that it is never too late to make a change and that banning antimicrobials from our food chain may have an almost instantaneous positive – and cost-saving – effect.

Around 2000, community-associated VRE began to appear in the US. In a screening study of patients attending an ambulatory care clinic in Nashville, Tennessee, 3 patients tested positive for VRE out of 100 patients screened. One of these patients came in for her annual check-up and had no prior healthcare exposures[23]. Also, VRE was found in wastewater from a semi-closed "agri-food" system[24]. Nonetheless, VRE remains an uncommon pathogen in community-associated infections. In 289 patients with community-onset VRE, 85% of patients had been hospitalized, and 71% had antimicrobial exposure in the last 3 months, respectively[25]. In another study that included 81 patients with community-onset VRE bacteremia, 79% of patients had prior hospitalizations[26]. These data indicate that even in those patients where VRE is detected on admission or early during hospitalization, acquisition likely occurred in the healthcare setting. This acquisition was driven by traditional risk factors of antimicrobial exposure, healthcare exposure, chronic illness, indwelling devices, malignancies and immunosuppression[25, 26].

The discrepancy between the community spread of MRSA and VRE is notable, as both *S. aureus* and enterococci are common human colonizers. However, overall colonization with enterococci is much more universal than with *S. aureus*, and *S. aureus* is not truly a commensal. Apparently – in contrast to MRSA – high prevalence of current strains of VRE in the community requires either an ongoing incoming supply of VRE into the shared community gut microbiome through the food chain, or a high level of antibiotic pressure. Fitness cost of maintaining a vancomycin resistant phenotype would be an intuitive explanation for the relative lack of true community-associated VRE infections. However, the fitness cost of vancomycin resistance appears to be minimal for enterococci, especially in the context of inducible resistance[27, 28]. A recent study suggests that pheromone-mediated killing of VRE may account for why vancomycin-susceptible commensal enterococci outcompete VRE in the human gut[29]. In this study, the prototype multidrug-resistant clinical isolate strain *E. faecalis* V583 was killed by human fecal flora, whereas commensal antibiotic-susceptible *E. faecalis* was able to survive in the presence of flora. The killing effect was traced to pheromone production by commensal *E. faecalis* strains[29].

Carbapenem-resistant Acinetobacter baumannii (CRAB)

Acinetobacter baumannii infections are commonly encountered in hospitalized patients, especially in the intensive care[30]. However, community-associated *A. baumannii* infections have been well-described especially in (sub-) tropical climates, including Asia and Australia[31]. These are generally associated with pharyngeal carriage and are linked to alcohol abuse and smoking[31]. These are serious infections and the attributable mortality in 80 patients with bacteremia and/or pneumonia from various case series was reported at 56%[31]. Community reservoirs for *A. baumannii* include environmental sources such as soil and vegetables, as well as human and animal skin and throat carriage. Furthermore, *A. baumannii* has also been recovered from human lice[32].

A. baumannii is intrinsically resistant to several antibiotic classes. In addition, carbapenem resistance may occur through acquisition of carbapenemases such as IMP-like carbapenemases and/or oxacillinases (OXA)[33]. The rate of carbapenem resistance in clinical isolates of *A. baumannii* rose sharply from 9% to 40% between 1995 and 2004 in the US[30].

More recent studies suggest that this rate has remained around 40%[34, 35]. In contrast, the rate of carbapenem resistance in *Acinetobacter* infections isolated from community-dwelling patients has remained around 4%[34]. Similarly, resistance to carbapenems was detected in only one out of 23 community-dwelling volunteers who had *A. baumannii* isolated from their hands[36]. In an Australian study on 36 patients with community-onset bacteremic *Acinetobacter* pneumonia, all tested isolates were susceptible to carbapenems[37]. A more worrisome report from China described 32 patients with community-acquired pneumonia caused by *A. baumannii*. Three and 6 isolates were non-susceptible to meropenem and imipenem, respectively. In addition, bla_{OXA-23} found in 12 of 15 tested isolates, some of which tested susceptible to both meropenem and imipenem[38]. Of note, 87% of patients with MDR *A. baumannii* had a "hospitalization history", suggesting that these did not truly represent community-associated infections[38].

In summary, community-associated CRAB appears to remain uncommon, likely reflecting the natural habitats of *Acinetobacter* species, and the differences between true community strains found to cause infections in Asia and Australia and hospital-associated strains. Of concern is the potential for acquisition of carbapenemases by such a community strain, especially in high antibiotic use areas in Asia.

Multi-drug resistant Pseudomonas aeruginosa

P. aeruginosa is a common cause of nosocomial infections, including bloodstream infections and pneumonia. It prefers moist environments and can be found in a large variety of places in the hospital, including sink traps and aerators, various equipment such as scopes and respiratory gear and contaminated solutions[39]. In addition, *P. aeruginosa* may be present on fresh fruit and vegetables as well as on the fingernails of healthcare providers[39].

Similar to *A. baumannii*, *P. aeruginosa* is intrinsically resistant to many antibiotic classes. Furthermore, additional acquired antibiotic resistance arises relatively easily and quickly after antibiotic exposure. Some patients have chronic biofilm-mediated pseudomonal colonization; patients with cystic fibrosis (CF) are an important example[40]. In these patients, repeated antibiotic courses are the rule, as is the subsequent development of MDR strains. While these patients are often community-dwelling, these infections are clearly healthcare-associated. Nonetheless, spread of MDR isolates between patients with CF has been well described and is an important infection control risk[41].

True community-associated infections with MDR *P. aeruginosa* fortunately remain very uncommon[42, 43]. In a cohort of 60 patients with community-acquired bloodstream infections with *P. aeruginosa*, 100% of isolates were meropenem susceptible, and 95% were susceptible to piperacillin/tazobactam and ceftazidime[44]. A case report from Turkey describes a young man without healthcare exposure who presented with a pyogenic liver abscess caused by a *P. aeruginosa* strain that was only susceptible to imipenem, amikacin, and colistin [45].

Enterobacteriaceae that produce extended spectrum β-lactamases

Enterobacteriaceae are very common causes of community-associated infections, including urinary tract infections and bacteremia. Unfortunately – in contrast to the situation described

above with *P. aeruginosa* and *A. baumannii* – there is widespread resistance in community-associated enterobacteriaceae isolates mediated by extended spectrum β-lactamases (ESBL) [46]. This is a global phenomenon and involves patients of all ages including pediatric populations. In a multicenter, prospective US study over a one year period in 2009-2010, 4% of E. coli community-onset isolates were ESBL producers[47]. The majority reflected urinary tract infections such as cystitis or pyelonephritis. The most common ESBL encountered were of the CTX-M group (91%), the remaining ESBLs were either SHV (8%) or CMY-2 (1%). Most isolates (54%) belonged to the ST131 clonal group[47]. *E. coli* ST131 is a globally disseminated MDR clone, and is characterized by resistance to fluoroquinolones in addition to production of CTX-M type ESBL[48].

In Asia, the Middle East, South America and some parts of Europe, community-onset infection with ESBL-producing *E. coli* is extraordinarily frequent. Lower prevalence regions include North America, some parts of Northern Europe, Australia and New Zealand. Specific risk factors for community-onset ESBL-producing *E. coli* infections have been found in these low prevalence regions. Reported risk factors from a Chicago-based study for ESBL-producing *E. coli* included travel to India (OR 14.4), increasing age (OR 1.04 per year), and prior use of ciprofloxacin (OR 3.92)[49]. In a German survey-based study, risk factors for ESBL-positive *E.coli* colonization included an Asian language being the primary language spoken in the household (OR 13.4) and frequent pork consumption (OR 3.5)[50]. A population-based study in London also suggested South-Asian ethnicity and older age as risk factors for ESBL-positive *E. coli* bacteriuria[51]. A study performed in Australia and New Zealand also found that birth on the Indian subcontinent or travel to SouthEast Asia, China, India, Africa or the Middle East were risk factors for community-onset third generation cephalosporin resistant *E. coli* infections[52].

A significant problem in Asia is disseminated infection with hypervirulent *Klebsiella pneumoniae* strains. These "hypermucoviscous" strains have a propensity to cause community-onset pyogenic liver abscess and sometimes metastatic infections, including meningitis[53]. While these strains were typically susceptible to multiple antibiotics, community-onset ESBL-producing strains are now well described and appear to be increasing[54].

Community-associated ESBL-producing enterobacteriaceae are of specific concern as treatment requires broad-spectrum antibiotics. A randomized controlled trial to address the question of comparative efficacy of piperacillin-tazobactam vs. meropenem to treat bloodstream infections caused by ceftriaxone non-susceptible *E. coli* and *Klebsiella* sp., showed that carbapenems were the more reliable choice[55]. Whether carbapenems are always indicated for infections caused by ESBL-producing organisms remains controversial. Tamma and colleagues in a recent observational study showed that piperacillin/tazobactam was as effective as carbapenems for complicated urinary tract infection in the absence of bloodstream infection[56]. A number of trials of "carbapenem-sparing" options for ESBL producing organisms are now planned or underway[57].

Carbapenemase-producing Enterobacteriaceae

Carbapenem-resistant enterobacteriaceae (CRE) represent an immediate public health threat that requires urgent and aggressive action[58, 59]. CRE are resistant to most antibiotics and clinical outcomes after CRE infections are generally poor[60-65]. While less frequent than carbapenem-resistant *Klebsiella pneumoniae* (CRKP), carbapenem resistant *E. coli* (CREC) constitute an important subset of CRE, and are on the rise globally and outbreaks have been reported in the US[66, 67]. To date, most CRE infections in the United States and Europe are health-care associated, with patients from long term care facilities at especially high risk[68]. Although data from Asia are somewhat sparse, carbapenemases have been found in bacteria recovered from drinking water in India and in food-producing animals in China[69, 70]. This raises the spectre of huge numbers of people in these large countries being colonized with CRE. It is now clear that hypervirulent Klebsiella can be carbapenem-resistant. This has been found in both Asia and elsewhere in the world, and has been associated both with KPC and other carbapenemase types [71-76]. A worrying development has been the finding of a transmissible plasmid which augments virulence in *K. pneumoniae* [77]. Disturbingly, this plasmid could be conjugated to carbapenem resistant strains, enabling them to simultaneously express carbapenem resistance and hypervirulence.

Given the rapid global spread of ESBL-producing *E. coli* ST131, another obvious concern is for this highly successful clone to acquire a carbapenemase. Indeed, several reports of carbapenemase-producing E. coli ST131 have been published[78-80]. In a study from India, ST131 clinical isolates were compared to non-ST131 clinical isolates. Overall 20% of clinical isolates were positive for metallo-β-lactamases such as bla_{NDM-1}, which was evenly distributed between ST131 and non-ST131 *E. coli*[79]. As the epidemiology of ESBL is estimated to be about 10 years ahead of that of the carbapenemases, it is likely that community-associated carbapenem-resistant ST131 *E. coli* will become a major threat in the near future.

Prevention

Prevention of further spread of MDR bacteria in the community is one of the most urgent public health challenges. Unfortunately, national or even regional data on antibiotic susceptibilities are often limited. In addition, when these data are available in some form, the accompanying epidemiologic metadata is usually too restricted to determine which isolates are truly community-associated. Furthermore, clinical infections are generally the tip of the proverbial iceberg and once a signal is generated that is sufficient in amplitude to get the attention of policy-makers, subclinical spread has already occurred.

Any successful prevention strategy will have to consist of a multi-pronged approach and involve all stakeholders. In addition to human clinical antimicrobial stewardship, we need to remove antibiotics from the food chain. Furthermore, we need to limit the amount of xenobiotics such as quaternary ammonium compounds that reach the environment[81]. Another challenging step in limiting exposure of bacteria to antibiotics is the treatment of contaminated wastewater such as that generated by pharmaceutical factories and medical facilities. For instance, a study evaluated samples collected from a wastewater treatment plant in India that received water from 90 regional bulk drug manufacturers containing

– amongst other compounds – higher concentrations of ciprofloxacin than are generally found in the blood of patients who are being treated with this agent. Bacteria recovered from this water were tested against 39 antibiotics. Approximately 30% of bacteria were resistant 29-32 antibiotics tested, and another ~20% were resistant to 33-36 antibiotics[82]. The magnitude of this effect, combined with the knowledge that soil-dwelling bacteria will pass on resistance genes to more clinically relevant bacteria, illustrates the importance of limiting this contamination[83].

Antimicrobial stewardship is developing rapidly as a hospital specialty. Stewardship teams often will combine strengths from Infectious Disease medical specialist and doctors of pharmacy to evaluate the appropriateness of choice and duration of antibiotic strategies[84]. However, most antibiotics are prescribed in ambulatory care and more attention is needed in this realm to really impact overall community antibiotic exposure[85]. This will not only require a paradigm shift in the behavior of prescribers, but also a cultural shift in the public on the risks and benefits of antibiotics. Rapid diagnostic testing to identify MDR bacteria more quickly and thus limit the empiric use of unnecessarily broad antibiotics will be of great significance. Also, rapid testing to diagnose alternative, non-bacterial etiologies is important.

An important question is whether any interventions can address the issue of chronic colonization with MDR bacteria. Obviously, decolonizing these patients would decrease the risk of transmission. Also, the burden on the individual patient of this condition should not be underestimated. In many healthcare systems, patients with MRSA or CRE are "labeled" as carriers for life, resulting in the institution of isolation precautions whenever they are admitted to the hospital. This has multiple adverse effects and leads to decreased patient satisfaction[86]. For these reasons, decolonization is a theoretically attractive option. However, most decolonizing strategies involve the use of antibiotics. For MRSA decolonization, most strategies involve some combination of intranasal mupirocin with topical chlorhexidine[87]. This approach has been shown to be effective in decreasing infections after surgery[88]. However, the effect is generally short-lived and recurrence of colonization is the rule. For enteric bacteria, no good options are currently available. Various selective gut decontamination strategies have been described, but none have shown true promise. In addition, with growing knowledge of the role of the gut microbiome in the defense against MDR bacteria, it would seem counter-intuitive to give even more antibiotics. Modulating the gut microbiome either through probiotics or through fecal microbiota transplantation is a promising, but as of yet experimental method of decolonizing patients.

Summary

In conclusion, antibiotic resistance is clearly increasing in bacterial pathogens typically regarded as community acquired. Additionally there is community spread of common nosocomial MDR pathogens. The success of these pathogens in the community is likely secondary to a number of factors that include the natural habitats of the bacteria, and the competition present in those niches. In addition, certain strains of bacteria appear to be much more able to maintain their MDR phenotype and spread throughout the community. This is most likely secondary to additional genetic content that compensates for the relative fitness

cost of the expression of genes associated with antibacterial resistance. Community spread of MDR bacteria is an important public health threat that should be approached urgently and pro-actively.

Acknowledgments

References

1. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. In: Department of Health and Human Services, ed. Atlanta, GA,U.S.: CDC, 2019.

2. Perez F, van Duin D. Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients. Cleveland Clinic journal of medicine 2013; 80: 225–33. [PubMed: 23547093]

3. Ena J, Dick RW, Jones RN et al. The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. Jama 1993; 269: 598–602. [PubMed: 8240468]

4. Friedman ND, Kaye KS, Stout JE et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Annals of internal medicine 2002; 137: 791–7. [PubMed: 12435215]

5. Morin CA, Hadler JL. Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998. The Journal of infectious diseases 2001; 184: 1029–34. [PubMed: 11574918]

6. American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. American journal of respiratory and critical care medicine 2005; 171: 388–416. [PubMed: 15699079]

7. Williamson D, Ingle D, Howden B. Extensively Drug-Resistant Shigellosis in Australia among Men Who Have Sex with Men. The New England journal of medicine 2019; 381: 2477–9. [PubMed: 31851807]

8. Namraj G, Monica ML, Marcus C et al. Molecular approaches to enhance surveillance of gonococcal antimicrobial resistance. Nature Reviews Microbiology 2014; 12: 223.

9. Su M, Satola S, Read T. Genome-Based Prediction of Bacterial Antibiotic Resistance. J Clin Microbiol 2019; 57.

10. Kollef HM, Betthauser DK. New antibiotics for community-acquired pneumonia. Current Opinion in Infectious Diseases 2019; 32: 169–75. [PubMed: 30640820]

11. DeLeo FR, Otto M, Kreiswirth BN et al. Community-associated meticillin-resistant Staphylococcus aureus. Lancet 2010; 375: 1557–68. [PubMed: 20206987]

12. Witte W Community-acquired methicillin-resistant Staphylococcus aureus: what do we need to know? Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2009; 15 Suppl 7: 17–25.

13. Saravolatz LD, Pohlod DJ, Arking LM. Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks. Annals of internal medicine 1982; 97: 325–9. [PubMed: 7114629]

14. Thurlow LR, Joshi GS, Richardson AR. Virulence strategies of the dominant USA300 lineage of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). FEMS immunology and medical microbiology 2012; 65: 5–22. [PubMed: 22309135]

15. Alam MT, Read TD, Petit RA 3rd et al. Transmission and microevolution of USA300 MRSA in U.S. households: evidence from whole-genome sequencing. mBio 2015; 6: e00054. [PubMed: 25759497]

16. Graveland H, Duim B, van Duijkeren E et al. Livestock-associated methicillin-resistant Staphylococcus aureus in animals and humans. International journal of medical microbiology : IJMM 2011; 301: 630–4. [PubMed: 21983338]

17. Murray BE. Vancomycin-resistant enterococcal infections. The New England journal of medicine 2000; 342: 710–21. [PubMed: 10706902]

18. Coque TM, Tomayko JF, Ricke SC et al. Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. Antimicrobial agents and chemotherapy 1996; 40: 2605–9. [PubMed: 8913473]

19. Silverman J, Thal LA, Perri MB et al. Epidemiologic evaluation of antimicrobial resistance in community-acquired enterococci. Journal of clinical microbiology 1998; 36: 830–2. [PubMed: 9508325]

20. Bruinsma N, Stobberingh E, de Smet P et al. Antibiotic use and the prevalence of antibiotic resistance in bacteria from healthy volunteers in the dutch community. Infection 2003; 31: 9–14. [PubMed: 12590326]

21. Bates J. Epidemiology of vancomycin-resistant enterococci in the community and the relevance of farm animals to human infection. The Journal of hospital infection 1997; 37: 89–101. [PubMed: 9364258]

22. Klare I, Badstubner D, Konstabel C et al. Decreased incidence of VanA-type vancomycin-resistant enterococci isolated from poultry meat and from fecal samples of humans in the community after discontinuation of avoparcin usage in animal husbandry. Microbial drug resistance 1999; 5: 45–52. [PubMed: 10332721]

23. D'Agata EM, Jirjis J, Gouldin C et al. Community dissemination of vancomycin-resistant Enterococcus faecium. American journal of infection control 2001; 29: 316–20. [PubMed: 11584258]

24. Poole TL, Hume ME, Campbell LD et al. Vancomycin-resistant Enterococcus faecium strains isolated from community wastewater from a semiclosed agri-food system in Texas. Antimicrobial agents and chemotherapy 2005; 49: 4382–5. [PubMed: 16189128]

25. Omotola AM, Li Y, Martin ET et al. Risk factors for and epidemiology of community-onset vancomycin-resistant Enterococcus faecalis in southeast Michigan. American journal of infection control 2013; 41: 1244–8. [PubMed: 24011554]

26. Wolfe CM, Cohen B, Larson E. Prevalence and risk factors for antibiotic-resistant community-associated bloodstream infections. Journal of infection and public health 2014; 7: 224–32. [PubMed: 24631369]

27. Foucault ML, Depardieu F, Courvalin P et al. Inducible expression eliminates the fitness cost of vancomycin resistance in enterococci. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 16964–9.

28. Johnsen PJ, Townsend JP, Bohn T et al. Retrospective evidence for a biological cost of vancomycin resistance determinants in the absence of glycopeptide selective pressures. The Journal of antimicrobial chemotherapy 2011; 66: 608–10. [PubMed: 21217128]

29. Gilmore MS, Rauch M, Ramsey MM et al. Pheromone killing of multidrug-resistant Enterococcus faecalis V583 by native commensal strains. Proceedings of the National Academy of Sciences of the United States of America 2015; 112: 7273–8.

30. Munoz-Price LS, Weinstein RA. Acinetobacter infection. The New England journal of medicine 2008; 358: 1271–81. [PubMed: 18354105]

31. Falagas ME, Karveli EA, Kelesidis I et al. Community-acquired Acinetobacter infections. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2007; 26: 857–68.

32. Eveillard M, Kempf M, Belmonte O et al. Reservoirs of Acinetobacter baumannii outside the hospital and potential involvement in emerging human community-acquired infections. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2013; 17: e802–5. [PubMed: 23672981]

33. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006; 12: 826–36.

34. Sengstock DM, Thyagarajan R, Apalara J et al. Multidrug-resistant Acinetobacter baumannii: an emerging pathogen among older adults in community hospitals and nursing homes. Clin Infect Dis 2010; 50: 1611–6. [PubMed: 20462357]

35. Queenan AM, Pillar CM, Deane J et al. Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. Diagnostic microbiology and infectious disease 2012; 73: 267–70. [PubMed: 22579652]

36. Zeana C, Larson E, Sahni J et al. The epidemiology of multidrug-resistant Acinetobacter baumannii: does the community represent a reservoir? Infection control and hospital epidemiology 2003; 24: 275–9. [PubMed: 12725357]

37. Davis JS, McMillan M, Swaminathan A et al. A 16-year prospective study of community-onset bacteremic Acinetobacter pneumonia: low mortality with appropriate initial empirical antibiotic protocols. Chest 2014; 146: 1038–45. [PubMed: 24901292]

38. Peng C, Zong Z, Fan H. Acinetobacter baumannii isolates associated with community-acquired pneumonia in West China. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2012; 18: E491–3.

39. Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43 Suppl 2: S43–8. [PubMed: 16894514]

40. Hassett DJ, Sutton MD, Schurr MJ et al. Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways. Trends in microbiology 2009; 17: 130–8. [PubMed: 19231190]

41. O'Malley CA. Infection control in cystic fibrosis: cohorting, cross-contamination, and the respiratory therapist. Respiratory care 2009; 54: 641–57. [PubMed: 19393108]

42. Rodriguez-Bano J, Lopez-Prieto MD, Portillo MM et al. Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2010; 16: 1408–13.

43. Anderson DJ, Moehring RW, Sloane R et al. Bloodstream infections in community hospitals in the 21st century: a multicenter cohort study. PloS one 2014; 9: e91713. [PubMed: 24643200]

44. Hattemer A, Hauser A, Diaz M et al. Bacterial and clinical characteristics of health care- and community-acquired bloodstream infections due to Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 2013; 57: 3969–75. [PubMed: 23733476]

45. Ulug M, Gedik E, Girgin S et al. Pyogenic liver abscess caused by community-acquired multidrug resistance Pseudomonas aeruginosa. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2010; 14: 218.

46. Pitout JD. Enterobacteriaceae that produce extended-spectrum beta-lactamases and AmpC beta-lactamases in the community: the tip of the iceberg? Current pharmaceutical design 2013; 19: 257–63. [PubMed: 22934977]

47. Doi Y, Park YS, Rivera JI et al. Community-associated extended-spectrum beta-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis 2013; 56: 641–8. [PubMed: 23150211]

48. Petty NK, Ben Zakour NL, Stanton-Cook M et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proceedings of the National Academy of Sciences of the United States of America 2014; 111: 5694–9.

49. Banerjee R, Strahilevitz J, Johnson JR et al. Predictors and molecular epidemiology of community-onset extended-spectrum beta-lactamase-producing Escherichia coli infection in a Midwestern community. Infection control and hospital epidemiology 2013; 34: 947–53. [PubMed: 23917909]

50. Leistner R, Meyer E, Gastmeier P et al. Risk factors associated with the community-acquired colonization of extended-spectrum beta-lactamase (ESBL) positive Escherichia Coli. an exploratory case-control study. PloS one 2013; 8: e74323. [PubMed: 24040229]

51. Gopal Rao G, Batura D, Batura N et al. Key demographic characteristics of patients with bacteriuria due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in a multiethnic community, in North West London. Infectious diseases 2015: 1–6.

52. Rogers BA, Ingram PR, Runnegar N et al. Community-onset Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countries. Antimicrobial agents and chemotherapy 2014; 58: 2126–34. [PubMed: 24468775]

53. Ko WC, Paterson DL, Sagnimeni AJ et al. Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerging infectious diseases 2002; 8: 160–6. [PubMed: 11897067]

54. Li W, Sun G, Yu Y et al. Increasing occurrence of antimicrobial-resistant hypervirulent (hypermucoviscous) Klebsiella pneumoniae isolates in China. Clin Infect Dis 2014; 58: 225–32. [PubMed: 24099919]

55. Harris PNA, Tambyah PA, Lye DC et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. Jama 2018; 320: 984. [PubMed: 30208454]

56. Tamma PD, Cosgrove SE. Unlikely Bedfellows: The Partnering of Antibiotic Stewardship Programs and the Pharmaceutical Industry. Clinical Infectious Diseases 2020.

57. Paterson DL, Henderson A, Harris PNA. Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia. Current Opinion in Infectious Diseases 2020; 33: 78–85. [PubMed: 31834029]

58. Spellberg B, Blaser M, Guidos RJ et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011; 52(Suppl 5): S397–428. [PubMed: 21474585]

59. Centers for Disease Control and Prevention. ANTIBIOTIC RESISTANCE THREATS in the United States, 2013. http://wwwcdcgov/drugresistance/threat-report-2013/ 2013.

60. Yigit H, Queenan AM, Anderson GJ et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrobial agents and chemotherapy 2001; 45: 1151–61. [PubMed: 11257029]

61. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. The Lancet infectious diseases 2009; 9: 228–36. [PubMed: 19324295]

62. Schwaber MJ, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. Jama 2008; 300: 2911–3. [PubMed: 19109119]

63. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. The Journal of antimicrobial chemotherapy 2010; Epub April 8, 2010.

64. Neuner EA, Yeh JY, Hall GS et al. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagnostic microbiology and infectious disease 2011; 69: 357–62. [PubMed: 21396529]

65. van Duin D, Kaye KS, Neuner EA et al. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagnostic microbiology and infectious disease 2013; 75: 115–20. [PubMed: 23290507]

66. Epstein L, Hunter JC, Arwady MA et al. New Delhi metallo-beta-lactamase-producing carbapenem-resistant Escherichia coli associated with exposure to duodenoscopes. Jama 2014; 312: 1447–55. [PubMed: 25291580]

67. Khajuria A, Praharaj AK, Kumar M et al. Emergence of Escherichia coli, Co-Producing NDM-1 and OXA-48 Carbapenemases, in Urinary Isolates, at a Tertiary Care Centre at Central India. Journal of clinical and diagnostic research : JCDR 2014; 8: DC01–4.

68. Bhargava A, Hayakawa K, Silverman E et al. Risk factors for colonization due to carbapenem-resistant Enterobacteriaceae among patients exposed to long-term acute care and acute care facilities. Infection control and hospital epidemiology 2014; 35: 398–405. [PubMed: 24602945]

69. Walsh TR, Weeks J, Livermore DM et al. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. The Lancet infectious diseases 2011; 11: 355–62. [PubMed: 21478057]

70. Wang Y, Wu C, Zhang Q et al. Identification of New Delhi metallo-beta-lactamase 1 in Acinetobacter lwoffii of food animal origin. PloS one 2012; 7: e37152. [PubMed: 22629360]

71. Gu D, Dong N, Zheng Z et al. A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study. The Lancet infectious diseases 2018; 18: 37–46. [PubMed: 28864030]

72. Huang Y-H, Chou S-H, Liang S-W et al. Emergence of an XDR and carbapenemase-producing hypervirulent Klebsiella pneumoniae strain in Taiwan. Journal of Antimicrobial Chemotherapy 2018; 73: 2039–46.

73. Karlsson M, Stanton RA, Ansari U et al. Identification of a Carbapenemase-Producing Hypervirulent Klebsiella pneumoniae Isolate in the United States. Antimicrobial agents and chemotherapy 2019; 63.

74. Liu Y, Long D, Xiang T-X et al. Whole genome assembly and functional portrait of hypervirulent extensively drug-resistant NDM-1 and KPC-2 co-producing Klebsiella pneumoniae of capsular serotype K2 and ST86. The Journal of antimicrobial chemotherapy 2019; 74.

75. Roulston KJ, Bharucha T, Turton JF et al. A case of NDM-carbapenemase-producing hypervirulent Klebsiella pneumoniae sequence type 23 from the UK. JMM Case Reports 2018; 5.

76. Zhang Y, Jin L, Ouyang P et al. Evolution of hypervirulence in carbapenem-resistant Klebsiella pneumoniae in China: a multicentre, molecular epidemiological analysis. The Journal of antimicrobial chemotherapy 2019.

77. Zheng R, Zhang Q, Guo Y et al. Outbreak of plasmid-mediated NDM-1-producing Klebsiella pneumoniae ST105 among neonatal patients in Yunnan, China.(Report). Annals of Clinical Microbiology and Antimicrobials 2016; 15.

78. Pannaraj PS, Bard JD, Cerini C et al. Pediatric carbapenem-resistant Enterobacteriaceae in Los Angeles, California, a high-prevalence region in the United States. The Pediatric infectious disease journal 2015; 34: 11–6. [PubMed: 25093977]

79. Hussain A, Ranjan A, Nandanwar N et al. Genotypic and phenotypic profiles of Escherichia coli isolates belonging to clinical sequence type 131 (ST131), clinical non-ST131, and fecal non-ST131 lineages from India. Antimicrobial agents and chemotherapy 2014; 58: 7240–9. [PubMed: 25246402]

80. Peirano G, Schreckenberger PC, Pitout JD. Characteristics of NDM-1-producing Escherichia coli isolates that belong to the successful and virulent clone ST131. Antimicrobial agents and chemotherapy 2011; 55: 2986–8. [PubMed: 21444703]

81. Hawkey PM, Jones AM. The changing epidemiology of resistance. The Journal of antimicrobial chemotherapy 2009; 64 Suppl 1: i3–10. [PubMed: 19675017]

82. Marathe NP, Regina VR, Walujkar SA et al. A treatment plant receiving waste water from multiple bulk drug manufacturers is a reservoir for highly multi-drug resistant integron-bearing bacteria. PloS one 2013; 8: e77310. [PubMed: 24204801]

83. Forsberg KJ, Reyes A, Wang B et al. The shared antibiotic resistome of soil bacteria and human pathogens. Science 2012; 337: 1107–11. [PubMed: 22936781]

84. Wagner B, Filice GA, Drekonja D et al. Antimicrobial stewardship programs in inpatient hospital settings: a systematic review. Infection control and hospital epidemiology 2014; 35: 1209–28. [PubMed: 25203174]

85. Gangat MA, Hsu JL. Antibiotic stewardship: a focus on ambulatory care. South Dakota medicine : the journal of the South Dakota State Medical Association 2015; **Spec No**: 44–8. [PubMed: 25985608] **Spec No**

86. Vinski J, Bertin M, Sun Z et al. Impact of isolation on hospital consumer assessment of healthcare providers and systems scores: is isolation isolating? Infection control and hospital epidemiology 2012; 33: 513–6. [PubMed: 22476279]

87. Coates T, Bax R, Coates A. Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects. The Journal of antimicrobial chemotherapy 2009; 64: 9–15. [PubMed: 19451132]

88. Chen AF, Wessel CB, Rao N. Staphylococcus aureus screening and decolonization in orthopaedic surgery and reduction of surgical site infections. Clinical orthopaedics and related research 2013; 471: 2383–99. [PubMed: 23463284]

Table 1.

Multidrug resistant bacteria observed in the community, classified according to CDC threat level.

MDR Phenotype	Epidemiologic setting of community-onset infections
Urgent Threats	
CR-AB	Extremely rare
Candida auris	Extremely rare
Clostridioides difficile	Prior antibiotic exposure; nursing homes
CRE	Rare at present; emerging in India and China
Drug-resistant *Neisseria gonorrhoeae*	Exclusively community-onset
Serious threats	
Drug-resistant *Campylobacter*	Exclusively community-onset
Drug-resistant Candida	Rare at present; prior azole exposure typical
ESBL + Enterobacterales	Endemic in most parts of the world
VRE	Rare except in nursing home residents
CR-PA	Extremely rare, except in those with suppurative lung disease and extensive antibiotic use
Drug-resistant nontyphoidal Salmonella	Exclusively community-onset
Drug-resistant Salmonella serotype Typhi	Exclusively community-onset
Drug-resistant Shigella	Exclusively community-onset
MRSA	Household colonization; farm animal exposure
Drug-resistant *Streptococcus pneumononiae*	Almost exclusively community-onset
Drug-resistant tuberculosis	Predominantly community-onset